MPN - 984
Comparative Efficacy, Hematologic Safety, and Treatment Persistence of FDA-Approved Janus Kinase Inhibitors in Myelofibrosis: Integrating the 2026 Approval of Once-Daily Ruxolitinib XR — A Systematic Review and Bayesian Network Meta-Analysis
Sangeetha Gandhi
Poster Presenter: Sangeetha Gandhi
